First Tracks Biotherapeutics (TRAX) Q1 2026 earnings summary

Executive summary

• Completed spin-off from AnaptysBio on April 20, 2026, becoming an independent, publicly traded biotech focused on antibody therapies for autoimmune and inflammatory diseases.

• Launched with $180 million in cash and equivalents, with a two-year cash runway to advance ANB033 and initiate Phase 2 trials across four indications.

• Pipeline includes ANB033 (celiac disease, eosinophilic esophagitis), rosnilimab (rheumatoid arthritis), and ANB101 (BDCA2 modulator).

• Q1 2026 financials reflect combined results and expense allocations post-separation.

Financial highlights

• Cash and cash equivalents were $248.5 million as of March 31, 2026, up from $38.0 million at December 31, 2025.

• Net loss for Q1 2026 was $50.5 million, compared to $47.2 million in Q1 2025.

• Research and development expenses decreased to $34.0 million from $41.5 million year-over-year, mainly due to lower clinical expenses.

• General and administrative expenses increased to $18.9 million from $9.8 million, driven by higher personnel, legal, and stock compensation costs related to the separation.

• Interest income for Q1 2026 was $4.1 million.

Outlook and guidance

• Management expects existing cash, cash equivalents, and investments to fund operations for at least the next 12 months, with a projected two-year cash runway.

• Top-line Phase 1b data for ANB033 in celiac disease expected in Q4 2026; eosinophilic esophagitis data anticipated mid-2027.

• Plans to continue advancing clinical trials for lead programs and may seek additional financing or partnerships.